Fenwick Represents Aliada Therapeutics in Pending Acquisition by AbbVie

Fenwick is representing Aliada Therapeutics, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases, in its pending acquisition by AbbVie (NYSE: ABBV), a pharmaceutical firm with a mission to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow.

Under the terms of the agreement, AbbVie will acquire all outstanding Aliada equity for $1.4 billion in cash, subject to certain customary adjustments. This transaction is expected to close in the fourth quarter of 2024, subject to regulatory approvals and other customary closing conditions. More information can be obtained from the announcement.

The Fenwick team includes corporate partners David Michaels and Effie Toshav and associates Rob O'Connor, David Rand, Philip Ewing, Susan Lee and Sarah Marshall; technology transaction partner Stefano Quintini, associates Pinar Bailey, Julia Chung, Aaron Dunn and Taylor Muentener and advisor Sandra Weustink; executive compensation and employee benefits partners Gerald Audant and Matt Cantor and associates Jonathan Stephenson and Melita Chan; tax partner Mike Knobler and associate Einav Axler; antitrust and competition partners Steve Albertson and Tom Ensign; healthcare regulatory partner Jennifer Yoo; and privacy and cybersecurity counsel Ana Razmazma.